



---

**Article: Oral vs. intravenous  
empirical antimicrobial therapy in  
febrile neutropenic patients receiving  
childhood cancer chemotherapy**

---

---

**Authors' reply**

---

Dear Editor,

I have read the recent publication in the journal with a great interest.<sup>1</sup> Cagol et al. concluded that "there was no difference in the outcome in oral vs. intravenous therapy."<sup>1</sup> There are some concerns and questions on this report. First, whether the number of subjects is statistically acceptable and whether there is any background differences among the subjects in both groups still require clarification. Second, it should be clarified that "no difference in the outcome" is related to the efficacy of the therapeutic alternative. However, there are no data on cost-effectiveness and cost-utility. Further studies on these aspects are needed.

**Viroj Wiwanitkit**

Professor, Wiwanitkit House,  
Bangkhuae, Bangkok, Thailand 10160.

doi:10.2223/JPED.2018

No conflicts of interest declared concerning the publication of this letter.

**References**

1. Cagol AR, de Castro Junior CG, Martins MC, Machado AL, Ribeiro RC, Gregianin LJ, et al. *Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy*. J Pediatr (Rio J). 2009;85:531-5.

We thank Professor Wiwanitkit for his comments on our report. Professor Wiwanitkit wonders whether there were background differences between both groups of patients and whether the number of patients in each arm allows a statistically acceptable interpretation. There was no apparent difference between patients in both arms as to age, gender, degree of neutropenia, disease status, and presence of comorbidities. We indeed found no difference in the outcome of patients receiving oral vs. intravenous therapy. We, however, pointed out in our paper that a prospective cooperative group trial with a larger number of patients is still required before we can make definitive recommendations on the safe use of oral therapy for febrile neutropenic (F&N) patients. In our paper, we also referred to other studies suggesting that low risk F&N patients can be successfully managed as outpatients. We believe there are limitations to a more widespread implementation of this approach, which include presence of medical comorbidities, social barriers and concurrent use of high-intensity chemotherapy protocols. In addition, there might be some reluctance by physicians to take additional risks, knowing that the established practice of inpatient management of F&N patients has a very low mortality rate.

**Algemir Brunetto**

Doutor. Chefe, Serviço de Oncologia Pediátrica, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.

**Lauro Gregianin**

Doutor, Oncologia Pediátrica, UFRGS, Porto Alegre, RS, Brazil. Médico Oncologista Pediátrico, Unidade de Oncologia Pediátrica, HCPA, UFRGS, Porto Alegre, RS, Brazil.

**Angela Rech Cagol**

Doutora, Oncologia Pediátrica, UFRGS, Porto Alegre, RS, Brazil. Professora adjunta, Pediatria, Universidade de Caxias do Sul (UCS), Caxias do Sul, RS, Brazil. Médica Oncologista Pediátrica, Unidade de Oncologia Pediátrica, HCPA, UFRGS, Porto Alegre, RS, Brazil.

doi:10.2223/JPED.2019

No conflicts of interest declared concerning the publication of this letter.